Therapeutic Response

BRAF p.V600K status confers therapeutic sensitivity to Trametinib in patients with Melanoma.

Statements

Source and description
Mekinist (trametinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to trametinib for the treatment of BRAF-inhibitor treatment-naive patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.
Mekinist (trametinib) [product monograph]. HC. Health Canada approved trametinib, as monotherapy or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Clinical data are stronger for BRAF V600E than V600K.